Immunotherapies
have evolved
Harnessing more of the immune system for better cancer outcomes
Latest News

We're looking for a highly skilled Senior Scientist to join our brilliant Functional Genomics & Screening Team. If this could be you, please respond to KSC 5-11 by Sunday 4 October 11:55pm AEDT.

#biotech #sci_jobs

http://careers.pageuppeople.com/513/cw/en/job/609303/senior-research-officer

Momentum is building in the allogenic CAR cell therapy space with CAR NK cells receiving a lot of attention @GileadSciences @KitePharma CSO comments on NK cell therapies in cancer via their partnership with @oNKo_innate

https://www.fiercebiotech.com/biotech/from-natural-killer-cells-to-off-shelf-car-ts-biopharma-targets-cancer-next-gen-cell

Load More...
 
Discover oNKo-innate
With our deep understanding of Natural Killer (NK) cells, we aim to be the first to master NK cell biology and therapeutically harness the cancer-fighting abilities of these remarkable white blood cells.
Learn more
OUR APPROACH
Using powerful genomic approaches, we screen primary immune cells and cancer cells to understand their interaction within a tumor.
Learn more
lab1-webRes
o o
o
THE TEAM
We are driven by the challenge of engaging the immune system to fight cancer, and focused on delivering the first truly effective NK cell immunotherapies.
Find out who we are